Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Chief Financial Officer | January 26, 2026 | January 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date January 26, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2036-01-25 | Direct | 303,000 |
Reported balance
After 2026-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 303,000 · Balance 303,000 F1: Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CymaBay Therapeutics, Inc.
Report date March 22, 2024 · Filed March 22, 2024
Section 16 reporting ended · disclosed 2024-03-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 1
1 source rowRow 1 · 2024-03-22 · Disposition to issuer · Disposed 20,125 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2033-05-21 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-22 · Disposition to issuer · Disposed 360,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.85 · Expires 2034-01-23 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-22 · Disposition to issuer · Disposed 74,750 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes.
F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2026 Filed Jan 28, 2026 16:30 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock option (right to buy) · Derivative | 303,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001193125-26-027290 · ownership.xml · derivative · entry 1 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,000 Underlying: Common Stock · 303,000 shares Expires 2036-01-25 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 16:01 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 198,750 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001193125-25-241380 · ownership.xml · derivative · entry 1 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,750 Underlying: Common Stock · 198,750 shares Expires 2035-10-14 F1 · derivative.exercise_date: One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 16:02 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 75,000 | $0.78 | $58,402.50 |
DisclosureSEC source: 0000950170-25-110434 · ownership.xml · nonDerivative · entry 1 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6823 to $0.9234, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 16:16 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001415889-25-010690 · form4-04152025_080423.xml · derivative · entry 1 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-04-11 F1 · derivative.exercise_date: All of the shares subject to the option vest on April 11, 2026. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 18:19 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-001969 · form4-01232025_110129.xml · derivative · entry 1 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2035-01-20 F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on January 21, 2026 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 17:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 74,750 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0000950170-24-035460 · ownership.xml · derivative · entry 3 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,750 shares Expires 2034-01-23 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 17:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 360,000 | Not disclosed Strike: $8.76 | Not disclosed |
DisclosureSEC source: 0000950170-24-035460 · ownership.xml · derivative · entry 2 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 360,000 shares Expires 2033-05-21 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 17:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerCommon Stock | 20,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-035460 · ownership.xml · nonDerivative · entry 1 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 18:33 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 74,750 | $0.00 Strike: $22.85 | $0.00 |
DisclosureSEC source: 0001062993-24-001435 · form4.xml · derivative · entry 2 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,750 Underlying: Common Stock · 74,750 shares Expires 2034-01-23 F2 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2024. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 18:33 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantCommon Stock | 20,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001435 · form4.xml · nonDerivative · entry 1 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,125 F1 · shares: The grant shall vest as to 1/4 of the shares on each of January 15, 2025, January 15, 2026, January 15, 2027 and January 15, 2028. Read SEC document |
| May 22, 2023 Filed May 22, 2023 17:13 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 360,000 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001062993-23-011932 · form4.xml · derivative · entry 1 Shantharam Harish · CIK 0001976391 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2033-05-21 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on May 22, 2024 and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.